Combining pegylated interferon α-2b with ruxolitinib for treating resistant polycythemia vera

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of pegylated interferon α-2b in combination with ruxolitinib compared to pegylated interferon α-2b alone in patients with polycythemia vera who are resistant or intolerant to hydroxyurea. Participants will be randomly assigned to receive either the combination treatment or pegylated interferon α-2b alone, with the option to switch treatments if necessary. The study will monitor hematologic responses and side effects over a specified treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old.
* Male or Female.
* Meets the diagnostic criteria for Polycythemia Vera according to WHO-2022.
* Resistant or intolerant to hydroxyurea (based on the 2013 European LeukemiaNet criteria).
* Have not previously received interferon preparations or ruxolitinib treatment, or the washout period between the last use of interferon preparations or ruxolitinib and the first use of the study drug should not be less than 4 weeks.
* Patients with indications for cytoreductive therapy.
* During screening, female hemoglobin (HGB) ≥10g/dL, male hemoglobin (HGB) ≥11g/dL; neutrophil count ≥1.5×109/L; platelet count ≥100×109/L.
* Voluntary written informed consent.

Exclusion Criteria:

* Symptomatic splenomegaly;
* Contraindications to interferon or ruxolitinib therapy;
* Severe or significant comorbidities that may affect the participant's ability to participate in the study, as determined by the investigator;
* History of major organ transplantation;
* Pregnant or breastfeeding women;
* History or current diagnosis of autoimmune thyroid disease (patients with controlled hypothyroidism on oral thyroid hormone replacement therapy may be included);
* Documented evidence of any other autoimmune disease (such as active hepatitis, systemic lupus erythematosus, antiphospholipid antibody syndrome, or autoimmune arthritis);
* Clinically significant bacterial, fungal, mycobacterial, parasitic, or viral infection such as active hepatitis or HIV infection (patients with acute bacterial infections requiring antibiotic treatment should be deferred from screening/enrollment until completion of antibiotic treatment);
* Evidence of severe retinopathy or clinically significant ophthalmologic disease (due to diabetes or hypertension);
* Current clinically significant depression or history of depression, or any suicidal attempt or tendency during screening;
* Active bleeding or thrombotic complications;
* History of any malignant tumor within the past 5 years (except for stage 0 chronic lymphocytic leukemia \[CLL\], cured basal cell carcinoma, squamous cell carcinoma, and superficial melanoma);
* History of alcohol or substance abuse within the past year;
* Presence of blasts in the peripheral blood within the past 3 months;
* Use of any investigational drug or participation in any other clinical trial within 4 weeks prior to the first dose of the study drug, or failure to recover from any effects of previously administered study drugs;
* The investigator deems the presence of any concurrent condition that may jeopardize the safety of the participant or the compliance to the protocol.

Where it's running

• Institute of Hematology & Blood Diseases Hospital
  Tianjin, China Recruiting

Study contacts

• Principal investigator: Lei Zhang, MD — Institute of Hematology & Blood Diseases Hospital, China
• Study coordinator: Lei Zhang, MD
• Email: zhanglei1@ihcams.ac.cn
• Phone: 8602223909240

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Ruxolitinib to treat symptoms of essential thrombocythemia and polycythemia vera

  This study is testing if the drug Ruxolitinib can help reduce symptoms for people with low-risk essential thrombocythemia and polycythemia vera.

  Recruiting at 3 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 3 other locations · NCT04644211

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• Comparing Ruxolitinib to Hydroxycarbamide or Interferon for High Risk Polycythemia Vera

  This study is testing whether ruxolitinib works better than hydroxycarbamide or interferon for people with high-risk polycythemia vera.

  Recruiting at 53 sites Phase 3 University of Birmingham · Aberdeen and 54 other locations · NCT04116502

• Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib

  We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07913672

• MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

  This study tests how outcomes differ for patients 16 and older with polycythemia vera, essential thrombocythemia, or myelofibrosis by collecting and analyzing clinical and treatment data.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07863466

• DMR-001 in CALR-mutant myeloproliferative neoplasms

  This study tests DMR-001 alone for CALR-mutant essential thrombocythemia or myelofibrosis, and in combination with ruxolitinib for CALR-mutant myelofibrosis.

  Recruiting at 3 sites Phase 1 Damora Therapeutics · Birmingham, Alabama and 35 other locations · NCT07849231

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.